Impact of low skeletal muscle mass index and perioperative blood transfusion on the prognosis for HCC following curative resection

CURRENT STATUS: UNDER REVIEW

BMC Gastroenterology  ▶ BMC Series

Tomoaki Bekki
Onomichi general hospital

Tomoyuki Abe  t.abe.hiroshima@gmail.com
Onomichi general hospital
Corresponding Author
ORCiD: 0000-0001-6859-7614

Hironobu Amano
Onomichi general hospital

Minoru Hattori
Hiroshima Daigaku Byoin

Tsuyoshi Kobayashi
Hiroshima Daigaku Byoin

Masahiro Nakahara
Onomichi general hospital

Hideki Ohdan
Hiroshima Daigaku Byoin

Toshio Noriyuki
Onomichi general hospital

DOI: 10.21203/rs.2.18870/v1

SUBJECT AREAS  Geriatrics & Gerontology
KEYWORDS

*blood transfusion, hepatocellular carcinoma, low SMI*
Abstract

Background This study aimed to assess the prognostic factors including low skeletal muscle mass index (SMI) and perioperative blood transfusion for patients with hepatocellular carcinoma (HCC) following curative surgery. Methods This study included 139 patients with HCC who underwent hepatectomy between 2005 and 2016. Univariate and multivariate analyses were performed to identify variables associated with overall survival (OS) and recurrence-free survival (RFS). Results Low SMI was significantly related with poor OS, while blood transfusion had a strong impact on RFS. The male ratio and body mass index in the low SMI group were significantly higher than those in the high SMI group. There were no significant differences in age, virus aetiology, laboratory data, liver function, tumour makers, and operative variables between the groups. Tumour factors such as tumour diameter, tumour number, poor differentiation, and intrahepatic metastasis (IM) did not significantly differ between the two groups. Operation time, intraoperative blood loss volume, and recurrence ratio were significantly higher in the blood transfusion group than in the non-transfusion group. IM was associated with poor OS and RFS. Conclusions Multidisciplinary support for recovering low SMI and reducing the use of blood transfusion would improve the long-term outcomes in patients with HCC following curative surgery. Low SMI and blood transfusion were independently related with long-term prognosis in patients with HCC following curative surgery.

Background

Hepatocellular carcinoma (HCC) is the sixth most common carcinoma and third leading cause of cancer-related deaths worldwide [1]. Progression of surgical
techniques and a better understanding of liver anatomy have played an important role in suppressing intraoperative blood loss [2, 3]. However, there is still substantial risk of perioperative blood loss in patients who undergo major hepatectomy, and the need for blood transfusion remains high [2]. From the aspect of immune surveillance for cancer, we formulated the following two hypotheses why perioperative blood transfusion should be avoided: 1) allogenic blood transfusion can increase the risk of virus infection, such as hepatitis B, hepatitis C, and human immunodeficiency syndrome [4, 5] and 2) it increases the risk of immunological complications due to postoperative infection, possibly leading to reduced long-term survival. Several studies have revealed that perioperative blood transfusions decreased the recurrence-free survival (RFS) and overall survival (OS) of patients after hepatectomy [6, 7]. Other reports have shown that perioperative blood transfusions does not influence RFS, OS, and disease-free survival (DFS) after hepatectomy [8, 9]. The influence of perioperative blood transfusion on tumor recurrence remains controversial.

Well-known prognostic variables such as tumor marker, advanced tumor stage, and vascular invasion were evaluated. Recently, tumor-associated variables and liver function have been strongly related to long-term prognosis. Honmyo et al. [10] reported that the albumin-bilirubin grade and albumin-indocyanine green evaluation grade were not only independent prognostic factors but also associated with postoperative complications. Preoperative nutritional status and immunological status were associated with postoperative complications and outcomes of patients with HCC such as obesity, Glasgow Prognostic Score (GPS) score, and neutrophil-to-lymphocyte ratio (NLR) [11-14]. Sarcopenia in HCC is also a well-known factor affecting long-term prognosis, based on the age, deteriorated immune status, and
tumor-bearing condition [15-17].

This retrospective study aimed to clarify the postoperative prognostic factors, especially blood transfusion and low skeletal muscle mass index (SMI), for HCC patients with Child–Pugh grade A following curative surgery.

Methods

Patients

Between 2005 and 2016, of the 175 patients with HCC who underwent hepatectomy at our institute, 139 patients who underwent hepatectomy for the first time were enrolled in this study. Patients with Child–Pugh grade B and who underwent repeat hepatectomy were excluded (Fig. 1). Following the guidelines of the Declaration of Helsinki (Fortaleza, Brazil, October 2013), this study was approved by the institutional review board of the Onomichi General Hospital (approval number: OJH201905).

Perioperative blood transfusion

Perioperative blood transfusion was defined as transfusion of red blood cells (RBCs). This study did not involve the use of other blood products such as fresh frozen plasma and platelet concentrates during the perioperative period. Perioperative blood transfusion was defined as the use of RBCs within the period of patients’ hospitalisation. The criteria for blood transfusion after surgery was a serum haemoglobin level of <7.0 mg/dl.

Definition of low SMI

SMI was measured on an axial section at the third lumbar vertebra (L3), which was taken 8 weeks prior to the surgery. They were segmented using standard Hounsfield unit (HU) ranges. Skeletal muscle was measured within the range of −29 to +150
HU, subcutaneous adipose was measured within the range of −190 to −30 HU, and abdominal adipose was measured within the range of −150 to −50 HU. Low SMI was defined as SMI <52.4 cm²/m² for men and <38.5 cm²/m² for women.

**Definition of intrahepatic metastasis (IM) and tumor number (solitary or multiple)**

Intrahepatic metastasis (IM) was defined as the tumor derived from the primary tumor. Multiple tumor was defined as the other tumor which is different from the primary tumor.

**Treatment and follow up**

A follow-up blood examination to identify tumor markers was performed every 3 months after surgery for 5 years. Enhanced abdominal CT was performed to rule out recurrence for 6 months. When HCC recurrence was suspected, magnetic resonance imaging was performed.

**Statistical analysis**

Values for continuous variables were presented as median and range. Nominal variables were expressed as numbers (%). Non-parametric quantitative data were analysed using Mann-Whitney U-test. Chi-square test was performed to determine the relationship among nominal variables. P-values <0.05 were considered significant. Calculations were performed using the SPSS software (version 22; IBM Corp., Armonk, NY, USA).

**Results**

**Prognostic factors for overall survival and recurrence-free survival identified by univariate and multivariate analyses**

Table 1 presents the prognostic factors for OS. On univariate analysis, the following
seven factors were statistically associated with poor OS: age >80 years (P = 0.002), HBV (P = 0.027), elevated protein induced by vitamin K absence or antagonist II (PIVKA-II) (P = 0.009), IM (P < 0.001), low SMI (P = 0.039; Fig. 2A), blood transfusion (P = 0.002; Fig. 3A), and Vp (P = 0.009). On multivariate analysis, the following four factors were revealed as independent poor prognostic factors of OS: age >80 years (HR = 1.979; P = 0.035), HBV (HR = 1.681; P = 0.035), IM (HR = 3.675; P < 0.001) and low SMI (HR = 2.006; P = 0.046). Table 2 presents the prognostic factors for RFS. On univariate analysis, the following six variables were associated with poor RFS: elevated protein induced by vitamin K absence or antagonist-II (PIVKA-II) (P = 0.048), elevated α-fetoprotein (AFP) (P = 0.036), tumor number (P = 0.025), IM (P < 0.001), blood transfusion (P = 0.008; Fig. 3B), and Vp (P = 0.016). On multivariate analysis, the following three factors were revealed as the poor prognostic factors of RFS: tumor number (HR = 1.810; P = 0.041), IM (HR = 4.115; P < 0.001) and blood transfusion (HR = 2.288; P = 0.008). There was no significant difference in RFS between patients with low SMI and those with high SMI. (Fig. 2B).

Characteristics of low SMI patients and high SMI patients with HCC

Table 3 provides a comparison of the perioperative characteristics between low SMI and high SMI patients with HCC. The male ratio in the low SMI group was higher than that in the high SMI group. The number of patients with low body mass index was significantly higher in the low SMI group than that in high SMI group. No significant differences were observed for age, NLR, prognostic nutritional index (PNI), and GPS between the groups. Tumor markers, liver function, and tumor-related factors were compatible between the two groups. The pattern of recurrence and type of treatment were not different between the two groups.
**Characteristics of patients with HCC who received blood transfusion and those who did not receive blood transfusion**

Table 4 presents the perioperative characteristics of the blood transfusion group and non-transfusion group with HCC. PNI of the transfusion group was lower than that of the non-transfusion group. With regard to the laboratory data, albumin levels and PIVKA-II were significantly higher in the transfusion group than those in the non-transfusion group. No significant differences were observed in the tumor-related factors between the two groups. Operation time and recurrence ratio were significantly higher in the transfusion group than those in the non-transfusion group.

**Discussion**

Several studies examining the prognosis of HCC patients following surgery have traditionally emphasized the effects of tumor-specific variables, lymph node metastasis, intrahepatic metastasis, and vascular invasion [18-21]. Undoubtedly, tumor-specific factors were related to the long-term prognosis; however, patient-related factors such as the immunological variables and sarcopenia have been reported as significant factors affecting the long-term prognosis. In the present study, low SMI and perioperative blood transfusion had a strong impact on long-term prognosis. Preoperative detection of low SMI is important to assess the prognosis in patients with HCC after curative surgery. Frailty is widely used as a metric of patient physiological reserve and overall health status. Recent studies have shown that skeletal muscle mass, which can be measured on CT cross-sectional imaging, is a marker of frailty and is used to detect sarcopenia [22, 23]. On the other hand, the European Working Group on Sarcopenia in Older People
recommended that sarcopenia should be diagnosed if both low muscles and low muscle function are present [24]. The efficacy of preoperative exercise and nutrition in patients with sarcopenia remains unclear; several studies have demonstrated that aerobic and resistance exercises are more effective in improving upper lower body muscle strength than the usual treatment [25, 26]. In addition, the skeletal muscle was recently recognized as an endocrine organ [27]. Interleukin (IL)-6, which may influence liver metabolism, is released from the skeletal muscle. IL-6 has already been identified as a factor with biological effects in patients with liver fibrosis and HCC [27]. Insulin-like growth factor (IGF)-1 was confirmed as a stimulatory factor in the development and regulation of skeletal muscle mass [27]. IGF-1 is mainly produced by the liver. Therefore, serum IGF-1 levels were low in patients with sarcopenia, and low IGF-1 levels result in the progression of HCC. Hence, there is a relationship between sarcopenia and HCC prognosis. Preventing muscle wasting is important for improving the prognosis of patients with HCC. In particular, patients with liver cirrhosis have decreased liver function, glycogen stores, and protein synthesis due to liver atrophy. Their consumption of amino acids from the skeletal muscle as an energy source increases, which causes progression of sarcopenia [28, 29]. There is a report showing that perioperative nutritional therapy using branched-chain amino acids improves OS of patients with cirrhosis and sarcopenia [30]. Multidisciplinary approach to overcome sarcopenia would improve the long-term prognosis of patients with HCC following curative surgery. Several previous studies have demonstrated that blood transfusion had a negative impact on the prognosis of HCC patients [6, 31]. In line with Harada et al.’s study, this study suggests that blood transfusion was associated with HCC recurrence after hepatectomy in patients with Child–Pugh class A. Recent studies
have reported that transfusion-related immunomodulation (TRIM) affects the prognosis of patients who received blood transfusion. RBCs transfusion was referred to as an immune system suppressor and has been linked to tumor recurrence [32]. The absolute peripheral blood lymphocyte count of patients who underwent blood transfusion is lower than that of patients who did not undergo blood transfusion [33]. There is one study that demonstrated that the natural killer cell activity of patients who underwent blood transfusion decreased on postoperative day 7 [34], leading to decreased tumor suppression. Additionally, blood transfusion cause secondary iron overload, which may accelerate the progression of liver fibrosis and recurrence of HCC [35]. The long-term prognosis of patients with distal cholangiocarcinoma who received perioperative RBCs transfusion was poorer than those who did not receive RBCs transfusion [36]. Moreover, intraoperative RBCs transfusion was associated with poor OS in patients with periampullary cancer who underwent pancreaticoduodenectomy [37]. In our study, patients in the blood transfusion group required longer operation time and had a larger volume of intraoperative blood loss than those in the non-transfusion group. Blood transfusion had a negative impact on RFS. Hence, it is important to avoid unnecessary blood transfusion and intraoperative blood loss to maintain the normal function of the host immune system.

This retrospective, single-centre study had a limited sample size. Future prospective cohort studies involving multiple institutions should be performed to confirm our results.

In conclusion, low SMI and perioperative blood transfusion were associated with long-term prognosis of HCC patients with Child–Pugh class A after curative surgery. Low SMI as an indicator of nutritional status, and transfusion-related immune
response was considered as independent risk factors for HCC. Perioperative nutrition management and advancements in surgical techniques, which can decrease perioperative blood loss, are essential for improving patient prognosis.

Abbreviations

SMI, skeletal muscle mass index; HCC, hepatocellular carcinoma; OS, overall survival; RFS, recurrence-free survival; IM, intrahepatic metastasis; DFS, disease-free survival; GPS, Glasgow Prognostic Score; NLR, neutrophil-to-lymphocyte ratio; RBCs, red blood cells; HU, Hounsfield unit; PIVKA-II, protein induced by vitamin K absence or antagonist-II; AFP, α-fetoprotein; PNI, prognostic nutritional index; IL, interleukin; IGF, insulin-like growth factor;

Declarations

Ethics approval and consent to participate

This study was authorized in advance by the institutional review board of the Onomichi General Hospital (approval number: OJH201905).

Consent for publication

All patients consented to the reporting of this case in a scientific publication.

Availability of data and materials

No applicable.

Competing interests

None of the authors has any financial conflict of interest related to this manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Authors’ contributions
T.B., T.A., and H.A. wrote the manuscript. All the authors read and approved the final manuscript.

Acknowledgments
We would like to thank the Center of Life Science at Hiroshima University for allowing us to use their facilities. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References
1. Ferlay J, Shin HR, Bray F, et al.: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Jarnagin WR, Gonen M, Fong Y, et al.: Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002; 236: 397-406.
3. Poon RT, Fan ST, Lo CM, et al.: Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg 2004; 240: 698-708.
4. Marcucci C, Madjdpour C and Spahn DR: Allogeneic blood transfusions: benefit, risks and clinical indications in countries with a low or high human development index. British medical bulletin 2004; 70: 15-28.
5. Tomimaru Y, Wada H, Marubashi S, et al.: Fresh frozen plasma transfusion does not affect outcomes following hepatic resection for hepatocellular carcinoma. World J Gastroenterol 2010; 16: 5603-10.
6. Harada N, Shirabe K, Maeda T, et al.: Blood transfusion is associated with
recurrence of hepatocellular carcinoma after hepatectomy in Child–Pugh class A patients. World J Surg 2015; 39: 1044–51.

7. Wada H, Eguchi H, Nagano H, et al.: Perioperative allogenic blood transfusion is a poor prognostic factor after hepatocellular carcinoma surgery: a multi-center analysis. Surg Today 2018; 48: 73–79.

8. Kuroda S, Tashiro H, Kobayashi T, et al.: No impact of perioperative blood transfusion on recurrence of hepatocellular carcinoma after hepatectomy. World J Surg 2012; 36: 651–8.

9. Yang T, Lu J-H, Lau WY, et al.: Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: A Propensity Score Matching Analysis. J Hepatol 2016; 64: 583–93.

10. Honmyo N, Kobayashi T, Hamaoka M, et al.: Comparison of new prognostic systems for patients with resectable hepatocellular carcinoma: albumin-bilirubin grade and albumin-indocyanine green evaluation grade. Hepatol Res, 2019.

11. Horino K, Beppu T, Kuroki H, et al.: Glasgow Prognostic Score as a useful prognostic factor after hepatectomy for hepatocellular carcinoma. Int J Clin Oncol 2013; 18: 829–38.

12. Harimoto N, Yoshizumi T, Shimagaki T, et al.: Inflammation-based prognostic score in patients with living donor liver transplantation for hepatocellular carcinoma. Anticancer Res 2016; 36: 5537–542.

13. Abe T, Tashiro H, Kobayashi T, et al.: Glasgow prognostic score and prognosis after hepatectomy for hepatocellular carcinoma. World J Surg 2017; 41: 1860–70.

14. Abe T, Amano H, Kobayashi T, et al.: Preoperative neutrophil-to-lymphocyte ratio as a prognosticator in early stage pancreatic ductal adenocarcinoma. Eur J Surg Oncol 2018; 44: 1573–9.
15. Voron T, Tselikas L, Pietrasz D, et al.: Sarcopenia impacts on short-and long-term results of hepatectomy for hepatocellular carcinoma. Ann Surg 2015; 261: 1173-83.

6. Kamachi S, Mizuta T, Otsuka T, et al.: Sarcopenia is a risk factor for the recurrence of hepatocellular carcinoma after curative treatment. Hepat Res 2016; 46: 201-8.

17. Harimoto N, Shirabe K, Yamashita YI, et al.: Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg 2013; 100: 1523-30.

18. Hao S, Fan P, Chen S, et al.: Distinct recurrence risk factors for intrahepatic metastasis and multicenter occurrence after surgery in patients with hepatocellular carcinoma. J Gastrointest Surg 2017; 21: 312-20.

19. Kim JM, Kwon C, Joh J-W, et al.: Intrahepatic metastasis is more risky than multiple occurrence in hepatocellular carcinoma patients after curative liver resection. Hepato-gastroenterology 2015; 62: 399-404.

20. Tsai T-J, Chau G-Y, Lui W-Y, et al.: Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 2000; 127: 603-8.

21. Esnaola NF, Lauwers GY, Mirza NQ, et al. Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg 2002; 6: 224-32.

22. Mitsiopoulos N, Baumgartner R, Heymsfield S, et al.: Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 1998; 85: 115-22.

23. Dodson RM, Firoozmand A, Hyder O, et al.: Impact of sarcopenia on outcomes
following intra-arterial therapy of hepatic malignancies. J Gastrointest Surg 2013; 17: 2123–32.

24. Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age and Ageing 2010; 39: 412-23

25. Cruz-Jentoft AJ, Landi F, Schneider SM, et al.: Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age and Ageing 2014; 43: 748-59.

26. Valenzuela T: Efficacy of progressive resistance training interventions in older adults in nursing homes: a systematic review. J Am Med Dir Assoc 2012; 13: 418-4128.

27. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012; 8: 457.

28. Tessari P. Protein metabolism in liver cirrhosis: from albumin to muscle myofibrils. Curr Opin Clin Nutr Metab Care 2003; 6: 79-85.

29. Dasarathy S. Consilience in sarcopenia of cirrhosis. J Cachexia Sarcopenia Muscle 2012; 3: 225-37.

30. Kaido T, Ogawa K, Fujimoto Y et al. Impact of sarcopenia on survival in patients undergoing living donor liver transplantation. Am J of Transplant 2013; 13: 1549-56.

31. Asahara T, Katayama K, Itamoto T, et al.: Perioperative blood transfusion as a prognostic indicator in patients with hepatocellular carcinoma. World J Surg 1999; 23: 676-80.

32. Vamvakas EC and Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2001; 97: 1180-95.

33. Sugita S, Sasaki A, Iwaki K et al. Prognosis and postoperative lymphocyte count
in patients with hepatocellular carcinoma who received intraoperative allogenic blood transfusion: a retrospective study. Eur J Surg Oncol (EJSO) 2008; 34: 339-45.

34. Kwon AH, Matsui Y, Kamiyama Y. Perioperative blood transfusion in hepatocellular carcinomas: influence of immunologic profile and recurrence free survival. Cancer 2001; 91: 771-8.

35. Itasaka H, Yamamoto K, Taketomi A et al. Influence of blood transfusion on postoperative long-term liver function in patients with hepatocellular carcinoma. Hepatogastroenterology 1995; 42: 465-8.

36. Lopez-Aguiar AG, Ethun CG, Pawlik TM, et al. Association of perioperative transfusion with recurrence and survival after resection of distal cholangiocarcinoma: A 10-institution study from the US extrahepatic biliary malignancy consortium. Ann Surg Oncol 2019; 26:1814–23.

37. Park HM, Park SJ, Shim JR, et al. Perioperative transfusion in pancreatoduodenectomy: The double-edged sword of pancreatic surgeons. Medicine (Baltimore) 2017; 96: e9019.

Tables

Table 1. Prognostic factors for overall survival identified by univariate and multivariate analyses (N = 139)
| Variables                          | n (%) | 3-year survival | 5-year survival | P-value |
|-----------------------------------|-------|----------------|----------------|---------|
| Male sex                          | 110 (79%) | 65.4% | 56.7% | 0.258 |
| Female sex                        | 29 (21%) | 88.5% | 68.5% | 0.002 |
| **Age (years)**                   |       |               |                |         |
| >80                               | 109 (78%) | 74.1% | 66.8% | <0.001 |
| ≤80                               | 30 (22%) | 54.1% | 33.7% |         |
| **BMI (kg/m²)**                   |       |               |                |         |
| >25                               | 34 (25%) | 74.4% | 63.0% | 0.441 |
| ≤25                               | 105 (75%) | 68.7% | 58.1% |         |
| **ALBI grade III**                |       |               |                |         |
| > grade III                       | 30 (22%) | 64.2% | 55.0% | 0.677 |
| ≤ grade III                      | 109 (78%) | 71.4% | 59.6% |         |
| **HBV (+)**                       |       |               |                |         |
| (-)                               | 27 (19%) | 78.3% | 78.3% | 0.027 |
| (+)                               | 112 (81%) | 67.9% | 52.7% |         |
| **HCV (+)**                       |       |               |                |         |
| (-)                               | 70 (50%) | 71.5% | 59.4% | 0.668 |
| (+)                               | 69 (50%) | 68.0% | 58.8% |         |
| **DM (+)**                        |       |               |                |         |
| (-)                               | 29 (21%) | 75.3% | 58.6% | 0.582 |
| (+)                               | 110 (79%) | 68.6% | 58.6% |         |
| **NLR ≥4**                        |       |               |                |         |
| >4                                | 13 (9%) | 52.6% | 52.6% | 0.257 |
| ≤4                                | 126 (91%) | 71.3% | 60.0% |         |
| **PLT (×10^4/μL): normal (13-35)** | |               |                |         |
| :abnormal                         | 42 (30%) | 63.1% | 55.4% | 0.094 |
| :abnormal                         | 95 (68%) | 74.2% | 63.7% |         |
| **PT (%): normal (70-130)**      |       |               |                |         |
| :abnormal                         | 125 (90%) | 72.3% | 60.4% | 0.172 |
| :abnormal                         | 14 (10%) | 46.2% | 46.2% |         |
| **AST (U/L): normal (13-33)**    |       |               |                |         |
| :abnormal                         | 71 (51%) | 78.6% | 59.9% | 0.086 |
| :abnormal                         | 68 (49%) | 61.1% | 56.5% |         |
| **ALT (U/L): normal (8-42)**     |       |               |                |         |
| :abnormal                         | 100 (72%) | 73.2% | 59.7% | 0.298 |
| :abnormal                         | 39 (28%) | 61.8% | 57.0% |         |
| **CHE (g/dL): normal (229-521)** |       |               |                |         |
| :abnormal                         | 77 (55%) | 74.6% | 64.0% | 0.110 |
| :abnormal                         | 62 (45%) | 63.6% | 52.6% |         |
| **Alb (g/dL): normal (4.0-5.0)**  |       |               |                |         |
| :abnormal                         | 115 (83%) | 72.2% | 60.3% | 0.165 |
| :abnormal                         | 24 (17%) | 58.4% | 51.9% |         |
| **T-chol (mg/dL): normal (128-219)** | |               |                |         |
| :abnormal                         | 118 (85%) | 71.7% | 59.1% | 0.732 |
| :abnormal                         | 20 (14%) | 66.9% | 66.9% |         |
| **PIVKA-II (mAU/mL): normal (<40)** | |               |                |         |
| :abnormal                         | 62 (45%) | 81.0% | 74.7% | 0.009 |
| :abnormal                         | 77 (55%) | 60.8% | 45.7% |         |
| **AFP (ng/mL): normal (>10)**    |       |               |                |         |
| :abnormal                         | 68 (49%) | 73.8% | 66.9% | 0.126 |
| :abnormal                         | 68 (49%) | 66.2% | 51.4% |         |
| **Tumor number: solitary**        |       |               |                |         |
| :multiple                         | 113 (81%) | 70.6% | 65.5% | 0.167 |
| :multiple                         | 26 (19%) | 67.9% | 37.0% |         |
| **Poor differentiation**          |       |               |                |         |
| Others (well, moderately)         | 119 (86%) | 69.2% | 61.1% | 0.545 |
| IM (+)                            | 19 (14%) | 34.1% | 22.7% | <0.001 |
| IM (-)                            | 120 (86%) | 77.1% | 66.0% |         |
| Vp (+)                            | 26 (19%) | 49.6% | 42.5% | 0.009 |
| Vp (-)                            | 113 (81%) | 74.6% | 62.8% |         |
| **Low SMI**                       |       |               |                |         |
| **High SMI**                      |       |               |                |         |
| Blood transfusion (+)             |       |               |                |         |
| (-)                               | 117 (84%) | 75.5% | 64.3% | 0.002 |

Variables in bold are statistically significant (P < 0.05). Abbreviations: BMI, Body mass index; ALBI, albumin-bilirubin; HBV, hepatitis type B; HCV, hepatitis type C; DM, diabetes mellitus; NLR, neutrophil-to-lymphocyte ratio; PLT, platelets; Hb, hemoglobin; PT, prothrombin time; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CHE, cholinesterase; Alb, albumin; T-chol, total-cholesterol; PIVKAII, protein induced by vitamin K absence or antagonist-II; AFP, α-fetoprotein; IM, intrahepatic metastasis; VP, portal vein invasion; SMI, skeletal muscle mass index.
### Table 2. Prognostic factors for recurrence-free survival identified by univariate and multivariate analyses (N = 139)

| Variables                  | n (%)              | 3-year survival | 5-year survival | P-value |
|----------------------------|--------------------|-----------------|-----------------|---------|
| Male sex                   | 110 (79%)          | 45.8%           | 41.2%           | 0.180   |
| Female sex                 | 29 (21%)           | 56.6%           | 40.4%           |         |
| Age (years) ≤80            | 109 (78%)          | 24.9%           | 24.9%           | 0.084   |
| >80                        | 30 (22%)           | 52.4%           | 45.2%           |         |
| BMI (kg/m²) ≥25            | 34 (25%)           | 48.0%           | 48.0%           | 0.699   |
| ALBI grade III ≤25         | 105 (75%)          | 48.3%           | 39.3%           | 0.708   |
| ALBI grade III >25         | 30 (22%)           | 49.5%           | 44.6%           |         |
| HBV (+)                    | 27 (19%)           | 63.2%           | 47.7%           | 0.236   |
| (-)                        | 112 (81%)          | 44.1%           | 37.7%           |         |
| HCV (+)                    | 70 (50%)           | 40.8%           | 38.6%           | 0.163   |
| (-)                        | 69 (50%)           | 56.4%           | 44.2%           |         |
| DM (+)                     | 29 (21%)           | 57.5%           | 43.6%           | 0.674   |
| (-)                        | 110 (79%)          | 45.2%           | 39.9%           |         |
| NLR ≥4                     | 13 (9%)            | 19.4%           | 19.4%           | 0.279   |
| <4                         | 126 (91%)          | 49.9%           | 42.5%           |         |
| PLT (×10⁴/μL): normal      | 97 (70%)           | 50.4%           | 42.4%           | 0.595   |
| :abnormal                  | 42 (30%)           | 44.1%           | 39.2%           |         |
| HB (g/dL): normal          | 95 (68%)           | 50.5%           | 41.6%           | 0.795   |
| :abnormal                  | 44 (32%)           | 44.3%           | 40.9%           |         |
| PT (%): normal (70-130)    | 125 (90%)          | 50.5%           | 42.3%           | 0.125   |
| :abnormal                  | 14 (10%)           | 28.8%           | 28.8%           |         |
| AST (U/L): normal (13-33)  | 71 (51%)           | 45.6%           | 33.9%           | 0.888   |
| :abnormal                  | 68 (49%)           | 51.1%           | 48.1%           |         |
| ALT (U/L): normal (8-42)   | 100 (72%)          | 48.8%           | 41.0%           | 0.770   |
| :abnormal                  | 39 (28%)           | 46.8%           | 40.9%           |         |
| CHE (g/dL): normal (229-521) | 77 (55%)    | 53.8%           | 44.9%           | 0.251   |
| :abnormal                  | 62 (45%)           | 41.7%           | 36.3%           |         |
| Alb (g/dL): normal (4.0-5.0) | 115 (83%) | 48.5%           | 39.8%           | 0.878   |
| :abnormal                  | 24 (17%)           | 46.7%           | 46.7%           |         |
| T-chol (mg/dL): normal     | 118 (85%)          | 49.4%           | 43.0%           | 0.907   |
| :abnormal                  | 20 (14%)           | 42.1%           | 31.6%           |         |
| PIVKA-II (mAU/mL): normal  | 62 (45%)           | 61.0%           | 51.0%           | 0.048   |
| (<40)                      |                   |                 |                 |         |
| :abnormal                  | 77 (55%)           | 37.7%           | 33.0%           |         |
| AFP (ng/mL): normal        | 68 (49%)           | 58.8%           | 48.3%           | 0.036   |
| (>10)                      | 68 (49%)           | 38.7%           | 33.5%           |         |
| Tumor number: solitary     | 113 (81%)          | 51.8%           | 44.5%           | 0.025   |
| : multiple                 |                   |                 |                 |         |
| Tumor size < 3 cm          | 71 (51%)           | 49.5%           | 43.4%           | 0.938   |
| ≤3 cm                      | 54 (39%)           | 52.6%           | 42.7%           |         |
| Poor differentiation       | 25 (18%)           | 42.1%           | 28.1%           | 0.337   |
| Others (well, moderately)  | 119 (86%)          | 49.3%           | 43.6%           |         |
| IM (+)                     | 19 (14%)           | 5.6%            | 5.6%            | 0.000   |
| (-)                        | 120 (86%)          | 56.1%           | 47.5%           |         |
| Vp (+)                     | 26 (19%)           | 28.4%           | 28.4%           | 0.016   |
| (-)                        | 113 (81%)          | 52.8%           | 43.5%           |         |
| Low SMI                    | 86 (62%)           | 46.1%           | 39.8%           | 0.335   |
| High SMI                   | 53 (38%)           | 51.9%           | 43.9%           |         |
| Blood transfusion (+)      | 22 (16%)           | 24.6%           | 24.6%           | 0.008   |
| (-)                        | 117 (84%)          | 52.4%           | 44.4%           |         |

Variables in bold are statistically significant (P < 0.05). Abbreviations: BMI, Body mass index; ALBI, albumin-bilirubin; HBV, hepatitis type B; HCV, hepatitis type C; DM, diabetes mellitus; NLR, neutrophil-to-lymphocyte ratio; PLT, platelets; Hb, hemoglobin; PT, prothrombin time; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CHE, cholinesterase; Alb, albumin; T-chol, total-cholesterol;
PIVKII, protein induced by vitamin K absence or antagonist-II; AFP, α-fetoprotein; IM, intrahepatic metastasis; Vp, portal vein invasion; SMI, skeletal muscle mass index

Table 3. Characteristics of low SMI and high SMI patients with hepatocellular carcinoma
### All patients (N=139) vs Low SMI patients (n=86) vs High SMI patients (n=53)

| Variable                      | All patients | Low SMI patients | High SMI patients |
|-------------------------------|--------------|------------------|-------------------|
| Male sex                      |              |                  |                   |
| Age (years)                   | 72 (32-92)   | 73 (36-92)       | 72 (32-84)        |
| **BMI (kg/m²)**               | 23 (16-33)   | 21 (16-27)       | 25 (18-33)        |
| HBV                           | 27 (19%)     | 16 (19%)         | 11 (21%)          |
| HCV                           | 70 (50%)     | 42 (49%)         | 28 (53%)          |
| DM                            | 29 (21%)     | 17 (20%)         | 12 (23%)          |
| NLR                           | 2 (0.3-7.4)  | 2 (0.3-7.4)      | 2 (0.5-6.1)       |
| **PNI ≤40**                    | 47.4 (34.3-59.9) | 47.1 (36.3-59.9) | 47.9 (34.3-58.8) |
| GPS ≥1                        | 24 (17%)     | 17 (20%)         | 7 (13%)           |
| PLT (×10⁴/μL)                 | 19 (4-51)    | 17 (4-51)        | 19 (6-49)         |
| PT (%)                        | 84 (56-128)  | 83 (56-109)      | 84 (59-128)       |
| T-Bil (mg/dL)                 | 0.8 (0.2-2.0)| 0.7 (0.2-1.8)    | 0.7 (0.3-2.0)     |
| AST (U/L)                     | 42 (11-130)  | 35 (14-127)      | 29 (11-130)       |
| ALT (U/L)                     | 37 (7-173)   | 31 (7-173)       | 28 (7-117)        |
| ChE (g/dL)                    | 234 (37-412) | 231 (86-410)     | 242 (37-412)      |
| Alb (g/dL)                    | 4 (3-5)      | 4 (3-5)          | 4 (3-5)           |
| ICGR15 (%)                    | 13 (0.1-89)  | 12 (0.1-89)      | 12 (0.1-75)       |
| AFP (ng/mL)                   | 10 (2-223330)| 9 (2-41013)      | 12 (2-233330)     |
| PIVKA-II (mAU/mL)             | 142 (12-675000) | 147 (12-675000) | 129 (14-39000)    |
| Tumor diameter >2 cm          | 34 (5-150)   | 38 (5-150)       | 30 (13-150)       |
| Tumor number                  | 1 (1-5)      | 1 (1-5)          | 1 (1-3)           |
| Poor differentiation           | 20 (14%)     | 13 (15%)         | 7 (13%)           |
| IM (+)                        | 19 (6%)      | 13 (15%)         | 6 (11%)           |
| Operation time (min)          | 303 (66-591) | 306 (89-591)     | 299 (66-582)      |
| Intraoperative blood loss (g) | 506 (0-6055) | 569 (0-6055)     | 405 (0-2100)      |
| Blood transfusion             | 22 (16%)     | 18 (21%)         | 4 (8%)            |
| Hospital stay (days)          | 22 (5-100)   | 21 (5-81)        | 24 (11-100)       |
| Recurrence                    | 74 (53%)     | 46 (53%)         | 28 (53%)          |

Variables in bold are statistically significant (P<0.05). Continuous variables are expressed as median (range). Qualitative variables are expressed as number (%).

Abbreviations: SMI, skeletal muscle mass index; BMI, Body mass index; HBV, hepatitis type B; HCV, hepatitis type C; DM, diabetes mellitus; NLR, neutrophil-to-lymphocyte ratio; PNI, prognostic nutritional index; GPS, Glasgow prognostic score.
PLT, platelets; PT, prothrombin time; T-Bil, total-bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ChE, cholinesterase; Alb, albumin; ICGR15, indocyanine green retention15; AFP, α-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist-II; IM, intrahepatic metastasis

Table 4. Comparison of the characteristics of patients who underwent transfusion and those who did not undergo transfusion
| Variable                               | All patients (N=139) | Transfusion (n=22) | Without transfusion (n=117) |
|----------------------------------------|----------------------|--------------------|-----------------------------|
| Male sex                               | 110 (79%)            | 18 (82%)           | 92 (79%)                    |
| Age (years)                            | 72 (32-92)           | 75 (57-88)         | 44 (32-92)                  |
| BMI (kg/m²)                            | 23 (16-33)           | 22 (17-30)         | 23 (16-33)                  |
| HBV                                    | 27 (19%)             | 3 (14%)            | 24 (21%)                    |
| HCV                                    | 70 (50%)             | 12 (55%)           | 58 (50%)                    |
| DM                                     | 29 (21%)             | 2 (9%)             | 27 (23%)                    |
| NLR ≥4                                 | 2 (0.3-7.4)          | 2 (0.9-5.8)        | 12 (0.3-7.4)                |
| **PNI ≤40**                            | 47.4 (34.3-59.9)     | 45 (37-51)         | 48 (34.3-59.9)              |
| GPS ≥1                                 | 24 (17%)             | 7 (32%)            | 17 (15%)                    |
| PLT (×10⁴/μL)                          | 19 (4-51)            | 15 (6-51)          | 18 (4-49)                   |
| PT (%)                                 | 84 (56-128)          | 83 (69-100)        | 84 (56-128)                 |
| T-Bil (mg/dL)                          | 0.8 (0.2-2.0)        | 0.7 (0.2-2.0)      | 0.7 (0.2-1.5)               |
| AST (U/L)                              | 42 (11-130)          | 39 (14-123)        | 31 (11-130)                 |
| ALT (U/L)                              | 37 (7-173)           | 27 (7-56)          | 30 (7-173)                  |
| ChE (g/dL)                             | 234 (37-412)         | 196 (86-346)       | 235 (37-412)                |
| Alb (g/dL)                             | 4 (3-5)              | 4 (3-4.3)          | 4 (3-5)                     |
| ICGR15 (%)                             | 13 (0.1-89)          | 13 (0.1-40)        | 13 (0.1-89)                 |
| AFP (ng/mL)                            | 10 (2-223330)        | 24 (4-65360)       | 8.4 (2-223330)              |
| **PIVKA-II (mAU/mL)**                  | 142 (12-675000)      | 428 (20-105000)    | 117 (12-675000)             |
| Tumor diameter > 2cm                   | 34 (5-150)           | 45 (15-150)        | 31 (5-150)                  |
| Tumor number                           | 1 (1-5)              | 1 (1-5)            | 1 (1-3)                     |
| Poor differentiation                   | 20 (14%)             | 3 (14%)            | 17 (15%)                    |
| IM (+)                                 | 19 (6%)              | 4 (18%)            | 15 (13%)                    |
| Operation time (min)                   | 303 (66-591)         | 383 (210-591)      | 282 (66-582)                |
| **Intraoperative blood loss (g)**      | 506 (0-6055)         | 820 (250-6055)     | 230 (0-2467)                |
| Hospital stay (days)                   | 22 (5-100)           | 20 (11-80)         | 17 (5-100)                  |
| Recurrence                             | 74 (53%)             | 14 (64%)           | 60 (51%)                    |

Variables in bold are statistically significant (P<0.05). Continuous variables are expressed as median (range). Qualitative variables are expressed as number (%).

Abbreviations: BMI, Body mass index; HBV, hepatitis type B; HCV, hepatitis type C, DM, diabetes mellitus; NLR, neutrophil-to-lymphocyte ratio; PNI, prognostic nutritional index; GPS, Glasgow prognostic score; PLT, platelets; PT, prothrombin
time; T-Bil, total-bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ChE, cholinesterase; Alb, albumin; ICGR15, indocyanine green retention15; AFP, α-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist-II; IM, intrahepatic metastasis

Figures

**Figure 1**

Study flowchart.
Figure 2

2A, 2B: Kaplan–Meier curve used to compare the low SMI group and high SMI group.
Figure 3

3A, 3B: Kaplan–Meier curve used to compare the transfusion group and non-transfus...